[ad_1]
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...